l e t t e r s 3 2 4 VOLUME 16 | NUMBER 3 | MARCH 2010 nature medicine An effective HIV vaccine must elicit immune responses that recognize genetically diverse viruses 1,2 . It must generate CD8 + T lymphocytes that control HIV replication and CD4 + T lymphocytes that provide help for the generation and maintenance of both cellular and humoral immune responses against the virus 3-5 . Creating immunogens that can elicit cellular immune responses against the genetically varied circulating isolates of HIV presents a key challenge for creating an HIV vaccine 6,7 . Polyvalent mosaic immunogens derived by in silico recombination of natural strains of HIV are designed to induce cellular immune responses that recognize genetically diverse circulating virus isolates 8 . Here we immunized rhesus monkeys by plasmid DNA prime and recombinant vaccinia virus boost with vaccine constructs expressing either consensus or polyvalent mosaic proteins. As compared to consensus immunogens, the mosaic immunogens elicited CD8 + T lymphocyte responses to more epitopes of each viral protein than did the consensus immunogens and to more variant sequences of CD8 + T lymphocyte epitopes. This increased breadth and depth of epitope recognition may contribute both to protection against infection by genetically diverse viruses and to the control of variant viruses that emerge as they mutate away from recognition by cytotoxic T lymphocytes.
Mosaic immunogen sequences are designed with an algorithm that simulates evolution by recombination, using coverage of potential T lymphocyte epitopes as the selection criterion 8 . Nine-amino-acid fragments are considered potential epitopes, as nine amino acids is the most common length of major histocompatibility complex (MHC) class I-presented peptides and the most common span between anchor residues of MHC class II-presented peptides 9 . These sequences form complete proteins and are created with recombination breakpoints that are found in nature. We initiated this study to explore the breadth of CD4 + and CD8 + T lymphocyte responses generated through vaccination with polyvalent mosaic and consensus immunogens.
We selected two HIV genes for use in the immunogens employed in this study 8 : HIV-1 gag and nef. We separated 30 rhesus monkeys into three cohorts, two experimental groups consisting of 12 monkeys each and a control group consisting of six monkeys. One experimental group received mosaic immunogens, the other experimental group received consensus immunogens, and the control group received empty vectors. We chose a DNA prime-recombinant vaccinia virus boost regimen for this study, as these immunogens elicit both CD4 + and CD8 + T lymphocyte responses [10] [11] [12] .
We determined the breadth of the vaccine-elicited cellular immune responses by assessing peripheral blood T lymphocyte recognition of ten natural Gag and Nef sequences with a peptide-stimulated interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) assay and matrix epitope mapping. The Gag and Nef sets of ten indicator proteins included two clade A, two clade B, four clade C and two clade G sequences (a clade of HIV-1 sequences is a group of genetically related, usually geographically discrete, virus isolates). We used the same set of sequences that we had previously used to evaluate vaccineelicited responses to a consensus Env immunogen 13 . We selected these isolate sequences to represent recently sampled viruses, diverse geographic origins and genetically distinct subregions of each clade. This strategy allowed us to assess vaccine-induced responses to sequences representative of the diverse HIV-1 strains to which human vaccinees will be exposed. Many nonamers in an HIV-1 strain are rare in the overall population of viruses (44% of Gag nonamers and 67% of Nef nonamers are present in <15% of wild-type sequences, on the basis of the Los Alamos database collection of M group sequences). As rare epitope variants are such a large component of the potential response, it is useful to know how often a vaccine can induce Mosaic vaccines elicit CD8 + T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys responses to rare nonamers in representative strains. This peptide design strategy allowed us to determine the precise number of vaccine-elicited responses per virus strain that were induced in each monkey and to characterize the cross-reactive potential of each epitope-specific response.
The magnitudes of the vaccine-induced Gag-specific and Nef-specific antibody and ELISPOT responses between the groups of monkeys were comparable ( Supplementary  Fig. 1a-c) ; therefore, any detected differences in the cross-reactivity of the cellular responses between these groups of vaccinated monkeys were not simply a manifestation of a more robust general immune response. The median number of epitope-specific total T lymphocyte responses generated by each monkey against Gag and Nef from a single virus strain after vaccination with consensus immunogens was 5.5 (interquartile range 3.0-11.75); the median number per strain after vaccination with mosaic immunogens was 7.75 (interquartile range 6.0-11.25). There was no statistically significant difference between these numbers of responses in the two experimental groups of monkeys (Wilcoxon rank-sum test).
To assess whether one of the vaccine strategies induced cellular immune responses that recognized a greater diversity of epitope variants, we determined the average number of variants recognized per epitope-specific response by dividing the total number of variant peptides recognized by the number of epitope-specific responses in each vaccinated monkey. The mosaic-vaccinated monkeys had higher ratios than the consensus-vaccinated monkeys (P = 0.045, Wilcoxon rank-sum test; Supplementary Table 1 ).
The vectors used in the present immunizations generated higher levels of CD4 + than of CD8 + T lymphocyte immune responses 12 , and any benefit for CD8 + T lymphocyte responses derived from using mosaic immunogens might be obscured in the overall response by the CD4 + T lymphocyte responses 14 . As CD4 + T lymphocytes recognize peptide antigens associated with MHC class II molecules, and peptide-MHC class II binding is more promiscuous than peptide-MHC class I binding, benefits associated with mosaic immunogens might be more apparent in CD8 + than CD4 + T lymphocyte responses 15, 16 .
To determine the relative impact of mosaic and consensus immunogens on CD8 + and CD4 + T lymphocyte responses separately, we evaluated the breadth of responses to HIV Gag and Nef that were generated by mosaic and consensus gene-based immunizations using unfractionated and CD8 + T lymphocyte-depleted peripheral blood lymphocyte (PBL) populations. Sufficient lymphocytes were available from seven monkeys in each of the vaccinated groups to carry out this evaluation.
We determined the total number of epitope-specific responses to all tested strains of Gag and Nef by PBLs of each monkey and compared the groups with the Wilcoxon rank-sum test (Fig. 1a) . The median number of epitope-specific CD4 + T lymphocyte responses per strain induced by vaccination of the monkeys with the mosaic immunogens was 4.5 (interquartile range 2.0-7.0), and it was 2.0 (interquartile range 1.25-4.0) in monkeys vaccinated with the consensus immunogens. The median number of epitope-specific CD8 + T lymphocyte responses per strain induced by vaccination of the monkeys with the mosaic immunogens was 2.0 (interquartile range 1.0-3.0), and it was 1.0 with the consensus immunogens (interquartile range 0.0-1.0) ( Supplementary Fig. 2 contains a full breakdown of responses by protein and by CD4 + and CD8 + T lymphocytes).
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Mosaic, CD4 237  65  134  75  81  95  59  237  65  134  75  81  95   58  101  93  262  228  271  114  58  101  93  262  228  271 There were more total T lymphocyte responses (CD4 + plus CD8 + ) per strain induced by Gag mosaic immunogens than by consensus immunogens by a factor of two (P = 0.023, Poisson regression), but vaccine-induced Nef responses did not differ significantly between the two groups.
We then compared the number of epitope-specific CD4 + and CD8 + T lymphocyte responses per monkey, counting overlapping peptides or sequence variants as one event (Fig. 1b) . There was no significant difference in the number of total (Gag-specific plus Nef-specific) (Wilcoxon rank-sum statistics; P = 0.28), Gag-specific (P = 0.18) or Nef-specific (P = 0.45) CD4 + T lymphocyte responses elicited by consensus or mosaic immunogens (Fig. 1b) . However, mosaic immunogens induced a significantly larger number of total (P = 0.001) and Gag-specific (P = 0.006) and a trend toward more Nef-specific (P = 0.158) CD8 + T lymphocyte responses.
We also assessed whether mosaic-immunized monkeys developed CD4 + and CD8 + T lymphocyte responses with greater depth than consensus-immunized monkeys by quantifying the number of responses to all of the variant forms of a given epitope (Fig. 1c) . There were more Gag-specific (P = 0.05) but not Nef-specific (P = 0.40) CD4 + T lymphocyte responses to variant peptides per response in the mosaic-immunized group; there was a median number of 1 (range 1-3) Gag epitope-specific CD4 + T lymphocyte response in the consensus-immunized monkeys and a median number of 3 (range 2-8) of such responses in the mosaic-immunized monkeys (Fig. 1c) . For CD8 + T lymphocyte responses, there were more total (Gag-specific plus Nef-specific) responses (P = 0.005), Gag-specific responses (P = 0.001) and a trend toward more Nef-specific responses (P = 0.16) in the mosaic-immunized monkeys than in the consensus-immunized monkeys (Fig. 1c) . These findings are comparable to those reported by Barouch et al. 17 in this issue (a median of 1 (range 0-2) in the consensus-immunized monkeys and a median of 3 (range 2-4) in the mosaic-immunized monkeys). Together, these data suggest that the benefit of the mosaic immunogens was more apparent for CD8 + T lymphocyte than for CD4 + T lymphocyte responses.
Because we evaluated the reactivity of the PBLs of each vaccinated monkey to peptides spanning the entire Gag and Nef proteins of ten genetically disparate HIV-1 isolates, we were able to define the immune recognition of actual proteins from distinct circulating virus strains in the immunized monkeys. Examples of typical responses and our approach to illustrating them are shown in Figure 2 ; the complete alignment of all peptides to which at least a single CD8 + T lymphocyte response was made is shown in Supplementary Figure 3 .
Some vaccine-induced CD8 + T lymphocyte responses were highly strain specific, capable of recognizing peptide variants from only one or two of the ten test strains (Figs. 2a,c and 3) . We observed broadly cross-reactive responses to individual epitopes, but they were very rare, with all ten peptide variants recognized only six times in all vaccinated monkeys ( Figs. 2b and 3) . There were some responses to two overlapping peptides, probably representing the recognition of a single epitope (Fig. 2b) . CD8 + T lymphocyte responses were usually highly specific. Extending the breadth of responses to more than two variant peptides was rare in both groups of vaccinated monkeys. This type of potentially valuable response occurred only six times among the consensus vaccine-induced CD8 + T lymphocyte responses and 17 times among responses in mosaic vaccine recipients (binomial test P = 0.03; Figs. 2d and 3) .
Modeling the depth of the peptide-specific responses as a function of vaccine and T lymphocyte type, we found that mosaic vaccine-elicited CD8 + T lymphocyte responses were more likely than consensus vaccine-elicited CD8 + T lymphocyte responses to recognize variant peptides by a factor of 1.6 (P = 0.0006, binomial regression; Fig. 3 and Supplementary Fig. 4) . Extending the breadth of a response to more than two variant peptides occurred 42 times among CD4 + T lymphocyte responses in the mosaic-immunized monkeys and only 23 times in the consensus-vaccinated monkeys (binomial test P = 0.05; Fig. 3 and Supplementary Figs. 5 and 6) . CD4 + T lymphocyte responses usually had greater depth (encompass a larger fraction of variants) than CD8 + T lymphocyte responses by a factor of 1.48 (P = 0.0004); this was true for both vaccine prototypes and may explain why the benefit of mosaic immunogens was more pronounced for CD8 + T lymphocytes. Almost all of the indicator strains of Gag and Nef proteins were recognized by one or two epitope-specific CD4 + T lymphocyte responses in the PBLs of both groups of vaccinated monkeys (Fig. 4a) . However, we detected more CD4 + T lymphocyte responses that recognized three epitopes in mosaic-vaccinated monkeys than in consensus-vaccinated monkeys. Almost all of the indicator strains of peptides were recognized by at least one epitope-specific CD8 + T lymphocyte response in the PBLs of the mosaic vaccine recipients, whereas a substantial number of viral strains were not recognized by epitope-specific CD8 + T lymphocyte peptide responses in the consensus-immunized monkeys (P = 0.057, Wilcoxon rank sum test; Fig. 4b) . The mosaic immunogens also elicited a significantly larger number of CD8 + T lymphocyte responses that recognized a minimum of two (P = 0.0022) and three epitopes (P = 0.0018) of these natural virus strains as compared to the consensus immunogen.
In the recent STEP human vaccine trial, an adenovirus-based HIV-1 Gag-Pol-Nef vaccine induced a median of only two epitope-specific responses to the vaccine in each subject (N. Frahm, personal communication), only 40% of the subjects mounted a response to Gag, and only 32% of vaccinees generated both a CD4 + and a CD8 + T lymphocyte response 18 . It is possible that this vaccine failed to confer protection because most of the vaccine-elicited responses were not able to recognize the circulating strains of HIV-1.
Our study demonstrates that immunization of nonhuman primates with mosaic immunogens induces CD8 + T lymphocytes with greater cross-reactivity than the consensus immunogen. The mosaic immunogens elicited CD8 + T lymphocyte responses to more epitopes of each viral protein than the consensus immunogens and to more variant sequences of the CD8 + T lymphocyte epitopes. This increased breadth and depth of epitope recognition could contribute to protection against infection by genetically diverse viruses and, in some instances, may block the emergence of common variant viruses. The stacks of ten rectangles represent the ten sets of indicator peptides with A1 and A2 shown in turquoise; B1 and B2 in red; C1, C2, C3 and C4 in purple; and G1 and G2 in dark blue. For each monkey, in the left-hand column (min 1), if at least one peptide from an indicator peptide set was recognized by either CD4 + (a) or CD8 + (b) T lymphocytes, the rectangle is shaded with its representative color. If no PBL responses to a particular set of indicator peptides were detected, the rectangle is shown unshaded. Recognition of one, two or three epitopes per strain of indicator proteins by CD4 + and CD8 + T lymphocytes of each of the seven monkeys in both vaccine groups is shown as min 1, min 2 and min 3, respectively. 
Figure 3
Breadth and depth of Gag-and Nef-specific CD8 + T lymphocyte responses in seven monkeys from each vaccine group. All of the Gag and Nef peptides recognized by PBLs of individual monkeys were aligned to the HIV-1 M group consensus sequences as described in the legend of Figure 2 . Lymphocyte recognition of any peptide sequence is shown in rectangles of shades of green, orange or yellow, and nonrecognition of a peptide is shown in unshaded rectangles.
